{"id":"daptacel-dtap","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Injection site erythema"},{"rate":"20-35","effect":"Injection site swelling"},{"rate":"40-50","effect":"Injection site pain"},{"rate":"15-25","effect":"Fever"},{"rate":"30-50","effect":"Fussiness/irritability"},{"rate":"25-40","effect":"Drowsiness"},{"rate":"10-20","effect":"Loss of appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAPTACEL contains inactivated diphtheria and tetanus toxoids along with acellular pertussis antigens. Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these three bacterial pathogens. This provides immunity against diphtheria, tetanus, and pertussis (whooping cough).","oneSentence":"DAPTACEL is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis toxins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:39.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against diphtheria, tetanus, and pertussis in infants and children (2 months to 6 years of age)"}]},"trialDetails":[{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT02118961","phase":"PHASE3","title":"Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":446},{"nctId":"NCT01129362","phase":"","title":"Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-02-08","conditions":"Pertussis","enrollment":1195},{"nctId":"NCT02697474","phase":"PHASE3","title":"Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT02610348","phase":"NA","title":"Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-11","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT00263692","phase":"PHASE2","title":"Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":401},{"nctId":"NCT00343421","phase":"PHASE3","title":"Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":588},{"nctId":"NCT00831753","phase":"PHASE3","title":"Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-05","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":263},{"nctId":"NCT00258895","phase":"PHASE3","title":"Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":649},{"nctId":"NCT00804284","phase":"","title":"Database Surveillance Safety Study of PENTACEL® Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":62538},{"nctId":"NCT01346293","phase":"PHASE3","title":"Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-04","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":3372},{"nctId":"NCT00404651","phase":"PHASE3","title":"Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1189},{"nctId":"NCT00401531","phase":"PHASE3","title":"Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Hepatitis B, Polio, Diphtheria","enrollment":412},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00255047","phase":"PHASE3","title":"Safety and Immune Response of Different Pediatric Combination Vaccines.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-11","conditions":"Diphtheria, Polio, Pertussis","enrollment":2167},{"nctId":"NCT00146835","phase":"","title":"Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Hepatitis B, Poliomyelitis, Diphtheria","enrollment":120794},{"nctId":"NCT00662870","phase":"PHASE3","title":"Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Diphtheria, Tetanus, Whooping Cough","enrollment":1941}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DAPTACEL®"],"phase":"phase_3","status":"active","brandName":"DAPTACEL®: DTaP","genericName":"DAPTACEL®: DTaP","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi-pasteur-a-sanofi-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"DAPTACEL is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis toxins. Used for Active immunization against diphtheria, tetanus, and pertussis in infants and children (2 months to 6 years of age).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}